Rhythm Pharmaceuticals to Outline Expected 2019 Milestones

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
23
Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference

- Updated clinical data from Phase 2 basket studies evaluating setmelanotide in Bardet-Biedl Syndrome (BBS) show continued weight loss for additional two patients at longer-term follow-up –

- Pivotal Phase 3 clinical trials in pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesity fully enrolled and on track for initial data anticipated in third quarter of 2019 followed by New Drug Application (NDA) filings -

- Combined pivotal Phase 3 clinical trial in BBS and Alström Syndrome on target and expected to complete enrollment in second half of 2019 -

BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM ), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that the company will outline expected 2019 milestones and review updated clinical data from its Phase 2 basket studies of setmelanotide in patients with BBS in a presentation at the 37 th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019. Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist.

“We expect 2019 to be an important year for Rhythm, marked by key advancements across our clinical development program for setmelanotide and culminating in preparations for the submission of our first NDA for POMC and LEPR deficiency obesity,” said Keith Gottesdiener, M.D., Chief Executive Officer of Rhythm. “Our significant achievements in 2018, including completing pivotal enrollment in our Phase 3 trials in POMC and LEPR deficiency obesity, initiating an additional pivotal trial in BBS and Alström Syndrome, and beginning to build an integrated patient community, have brought us closer to providing a first-in-class therapeutic option for people living with rare genetic disorders of obesity who have no approved treatments for reducing body weight and hunger.”

Updated BBS Data from Phase 2 Basket Studies and Pivotal Phase 3 Trial Design

Today, Rhythm announced updated clinical data from two adolescent patients in its Phase 2 basket studies evaluating setmelanotide for the treatment of BBS who previously had only short-term results (18 and 15 weeks of total treatment). Data is now available for 47 and 41 weeks of treatment. These two patients have lost 11.2% (-13.7 kg) and 15.5% (-13.7 kg) of their body weight and experienced hunger score reductions of 66% and 21%, respectively. Treatment with setmelanotide continues to be well tolerated and safety data were consistent with previous clinical studies. In total, six out of nine BBS patients enrolled in the Phase 2 basket studies have now achieved a clinically meaningful weight loss of 10% change from baseline, which is the primary endpoint for the company’s pivotal Phase 3 clinical trial, and, as previously reported, one additional patient with Type-1 diabetes responded with marked improvements in hunger score and blood sugar levels.

In December 2018, Rhythm began treating patients in a combined pivotal Phase 3 clinical trial evaluating setmelanotide in BBS and Alström Syndrome and expects to complete pivotal enrollment of at least 20 patients with BBS and at least six patients with Alström Syndrome in the second half of 2019.

Progress in Phase 3 Clinical Trials in POMC and LEPR Deficiency Obesity

Rhythm’s ongoing, separate pivotal Phase 3 clinical trials evaluating setmelanotide in POMC and LEPR deficiency obesity continue to progress, with topline data expected in the third quarter of 2019. Pending positive results, the company expects to submit an NDA filing for each of POMC and LEPR deficiency obesity to the U.S. Food and Drug Administration (FDA) in late 2019 or early 2020.

“In 2019, Rhythm expects to make significant strides toward our vision of becoming a fully-integrated biotechnology company, as we approach the anticipated submissions of concurrent NDAs for setmelanotide in POMC and LEPR deficiency obesity,” said Murray Stewart, M.D., Chief Medical Officer of Rhythm. “As we advance toward this milestone, we are working hard to build an integrated community of patients, physicians, payors and caregivers, in order to better understand the burden of these disorders and ensure that people living with these conditions are diagnosed and readily able to access treatment.”

Additional Development Pipeline Updates

Rhythm continues to evaluate setmelanotide for the treatment of additional rare genetic disorders of obesity in its Phase 2 basket studies, including POMC and other MC4R pathway deficiency heterozygous obesities, as well as POMC epigenetic disorders. The company expects to announce updated interim data from these disorders in the first quarter of 2019. In addition, Rhythm is continuing to expand the evaluation of setmelanotide into additional MC4R pathway disorders in its Phase 2 basket studies.

Webcast Information

Rhythm will webcast its corporate presentation from the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 10:00 a.m. PST (1:00 p.m. EST). Live webcasts of the presentation and subsequent breakout session can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website at www.rhythmtx.com . A replay of the webcasts will be available on the Rhythm website for 30 days.

About Setmelanotide

Setmelanotide is a potent, first-in-class, MC4R agonist in development for the treatment of rare genetic disorders of obesity. Setmelanotide activates MC4R, part of the key biological pathway that independently regulates energy expenditure and appetite. Variants in genes within the MC4R pathway are associated with unrelenting hunger and severe, early-onset obesity. Rhythm is currently developing setmelanotide as a replacement therapy for patients with monogenic defects upstream of MC4R, for whom there are no effective or approved therapies. The FDA has granted Breakthrough Therapy designation to setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway, which includes POMC deficiency obesity, LEPR deficiency obesity, BBS and Alström Syndrome. The European Medicines Agency has also granted PRIority MEdicines (PRIME) designation for setmelanotide for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4R pathway.

About Rhythm

Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the company’s first-in-class MC4R agonist, in Phase 3 studies in patients with POMC deficiency obesity, LEPR deficiency obesity, BBS, and Alström Syndrome. Rhythm is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. For healthcare professionals, visit www.UncommonObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information. The company is based in Boston, MA.

Forward-Looking Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements regarding Rhythm's expectations regarding its expectations for 2019, anticipated timing for enrollment and design of clinical trials, the timing for filing of an NDA, and the release of results of clinical trials. Statements using word such as "expect", "anticipate", "believe", "may", "will" and similar terms are also forward looking statements.  Such statements are subject to numerous risks and uncertainties, including but not limited to, our ability to enroll patients in clinical trials, the outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, and expenses, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannahd@sternir.com

Media Contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Lives with Sober.Buzz: Embrace the $BUZZ Journey

Updated Category News Views 568

Welcome to Sober.Buzz and the Journey of Transformation Sober.Buzz introduces the Sober Token, known for its symbol $BUZZ, representing a promising initiative aimed at creating a supportive and empowering global community for individuals in recovery from addiction. Designed by those who understand the struggles, the project offers hope and encouragement for those seeking...

Continue Reading
Revolutionizing Ecommerce with Artifi's AI Product Setup Tool

Updated Category News Views 188

Introduction to Artifi's New AI Feature Artifi, a dynamic player in SaaS solutions for product customization, has announced a groundbreaking new feature known as AI Automated Product Setup. This innovative tool aims to drastically reduce setup times, allowing suppliers to efficiently prepare their product data for ecommerce platforms. Understanding the Setup Process The...

Continue Reading
Cleeng Pro: Revolutionizing D2C Subscription Management Today

Updated Category News Views 180

Cleeng Pro: An Innovative Platform for D2C Subscriptions Cleeng, a leader in Subscriber Retention Management, has recently introduced Cleeng Pro, a groundbreaking direct-to-consumer (D2C) subscription platform. This platform empowers creators, developers, and entrepreneurs to establish their subscription services with remarkable efficiency, all without any cost for their...

Continue Reading
SciBase's Nevisense Device Sold to NIH: A New Era in Dermatology

Updated Category News Views 255

SciBase Holding AB hit the headlines back in 2024 when it announced the sale of its flagship device, Nevisense, to the National Institutes of Health (NIH). Traders were buzzing, not just because SciBase is known for its cutting-edge dermatology tech, but because this sale signaled a massive leap into uncharted territory regarding skin health. The NIH isn't just any buyer;...

Continue Reading
FLUENT Launches Innovative MOODS Black in the Sunshine State

Updated Category News Views 262

FLUENT Launches Innovative MOODS Black in the Sunshine State FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF), a leading national cannabis company, is thrilled to announce the exciting launch of its latest product, MOODS Black. This new addition to the well-regarded MOODS lineup showcases high-potency cannabis oil infused with cannabis-derived terpenes, ensuring a superior and...

Continue Reading